Expertise in
13
conditions

Rossella Elisei

Via Paradisa 2, 
Pisa, IT 
Expertise in
13
conditions
Via Paradisa 2, 
Pisa, IT 

Overview

Rossella Elisei practices practicing medicine in Pisa, Italy.

Ms. Elisei is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Medullary Thyroid Carcinoma, Thyroid Cancer, Papillary Thyroid Cancer, Thyroidectomy, and Pancreaticoduodenectomy.

She is actively involved in clinical research, co-authoring 281 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Via Paradisa 2, Pisa, 56124, Italy
Other Locations
Lungarno, 56126, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
View 1 Less Clinical Trial

281 Total Publications

Impairment in the hypothalamic-pituitary-gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib.
Impairment in the hypothalamic-pituitary-gonadal axis in males with medullary thyroid carcinoma treated with selpercatinib.
Journal: The Journal of clinical endocrinology and metabolism
Published: April 03, 2026

Frequently Asked Questions about Rossella Elisei

Is Rossella Elisei a top-rated expert for Medullary Thyroid Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Rossella Elisei is classified as an Elite expert for Medullary Thyroid Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Rossella Elisei participate in research or clinical trials?

Yes. Rossella Elisei has published 281 articles and abstracts on conditions like Medullary Thyroid Carcinoma. You can view a list of Rossella Elisei's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Elisei's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile